Mechanism Of Action

Erythropoietin (EPO) synthesizes primarily in renal cortical interstitial cells.
Stimulates proliferation and terminal differentiation of erythroid precursors.

Summary Of Clinical Indications

Clinical Condition	Agent And Dosage	Clinical Rationale And Remarks
Chronic Kidney Disease	Epoetin alfa/beta: 20-50 IU/kg 3x/week. Darbepoetin: 0.45 $\mu$g/kg weekly.	Mainstay therapy replacing absent endogenous EPO. Requires concurrent iron.
Anemia Of Prematurity	Recombinant EPO or Darbepoetin.	Stimulates reticulocytosis. Routine early use not recommended due to toxicity risks.
Autoimmune Hemolytic Anemia	Epoetin alfa: 20,000-40,000 IU/week.	Specifically indicated for severe, refractory disease featuring reticulocytopenia.
AIDS-Associated Cytopenia	Standard dosing.	Reverses anemia induced by antiretroviral therapy (zidovudine).

Represents primary indication for recombinant human EPO (rHuEPO) therapy.
Initiation Criteria: Initiated based on clinical judgment when hemoglobin falls below 11.0 g/dL (0.5-5 years), 11.5 g/dL (5-12 years), or 12.0 g/dL (12-15 years).
Dosing Regimens:
- Epoetin alfa/beta: 20-50 IU/kg administered subcutaneously three times weekly.
- Darbepoetin-alfa (synthetic analog): 0.45 $\mu$g/kg once weekly or 0.75 $\mu$g/kg every 2 weeks. Features longer half-life enabling less frequent dosing.
Therapeutic Targets:
- Goal hemoglobin: 11-12 g/dL (do not exceed 14 g/dL).
- Target increase: 1-2 g/dL over 4-week period.
Dose Titration:
- Non-responders: Increase dose up to maximum 300 IU/kg/day three times weekly.
- Rapid rise (>4% hematocrit in 2 weeks): Reduce dose by 25%.
- Hematocrit >40%: Suspend therapy. Restart at 75% initial dose once hematocrit falls to 36%.
Adjunctive Therapy: Mandatory concurrent iron supplementation to meet heightened erythropoietic demand.

Stimulates neonatal erythropoiesis, raising reticulocyte counts and hemoglobin.
Physiologic Advantage: Induces rightward shift in oxyhemoglobin dissociation curve via increased erythrocyte 2,3-bisphosphoglycerate content.
Limitations:
- Delayed therapeutic response (takes approximately 2 weeks).
- Fails to provide prompt correction in acute symptomatic states.
Contraindications: Routine early use NOT recommended. Associated with conflicting data regarding increased risks of severe retinopathy of prematurity (ROP) and necrotizing enterocolitis.

Utilized specifically for severe, refractory cases presenting with reticulocytopenia (due to autoantibody removal of reticulocytes or hypoplastic marrow response).
Dosing: Epoetin alfa 20,000-40,000 IU per week.
Efficacy: Successfully increases hemoglobin and reticulocytes in approximately 70% of treated children.

Anemia Of Inflammation: Efficacious in severe inflammatory states (e.g., inflammatory bowel disease) when profound inhibitory effects on erythropoiesis render isolated intravenous iron administration ineffective.
AIDS-Associated Cytopenia: Significantly improves hematocrit and reduces transfusion requirements during zidovudine (AZT) therapy.
Thermal Injury: Reverses diminished red blood cell production secondary to extensive burn-induced marrow suppression.
Paroxysmal Nocturnal Hemoglobinuria (PNH): Employed as supportive therapy for associated marrow failure.

Demonstrated efficacy in mitigating chemotherapy- and radiation-induced anemia, reducing transfusion requirements.
Pediatric Limitations: Routine use lacks support in pediatric oncology.
Precluded by unclear quality of life benefit, questionable cost-effectiveness, and potential severe risks including thromboembolism, tumor progression, and worsened overall survival.

Hypertension: Occurs in up to 30% of patients; mediated by increased blood viscosity.
Thromboembolism: Markedly increased risk of vascular thrombosis.
Increased Mortality: Associated with high-dose therapy regimens.
Immune Cytopenia: Rare development of anti-EPO antibody-mediated pure red cell aplasia. Mandates immediate cessation of therapy and consideration of immunosuppression.